A preclinical study of allogeneic <scp>CD19</scp> chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignanciesDan Wang, Liming Yang, Shuai Liu et al.|Clinical & Translational Immunology|2024Cited by 2